epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

Evidence library

What makes a site, or a country, recruit?

The evidence behind every number on the site: kinds of site and what each country brings, how each number was settled, and the register of risks it all draws on.

The risk register

Protocol and design

EB-01Overestimated eligible pool (Lasagna's law) Grade B
Effect
Negative; the commonest cause of recruitment-related discontinuation, first-quarter recruitment slower than planned in 63% of UK trials, and realistic yield quoted second-hand as one-tenth to one-third of the estimate.
What helped
Internal pilot with an explicit projection equation and stop-go review (Bertram 2019, descriptive); pre-trial accrual assessment (Schroen 2010: 67% against 47% sufficient accrual); evidence-based feasibility (CTTI 2018, no numbers).
What did not
A formal pilot phase as such (McDonald 2006: OR 1.09, no association); time extensions alone (Sully 2013: 55% against 54% reached target).
Sources
Briel 2016; McDonald 2006; van der Wouden 2007; Lasagna 1979; Feinstein 2001 via Bogin 2022
Watched by
The study's KPIs
EB-03Blinded placebo-controlled design instead of open-label Grade A
Effect
Open design recruits 10 percentage points more of eligible patients (95% CI 7 to 13); at trial level active-comparator trials failed accrual more often than placebo trials (23% against 16%), and per-centre rates did not differ significantly.
What helped
Open-label or pragmatic design where scientifically acceptable (high certainty).
What did not
not found
Sources
Treweek 2018; Carlisle 2015; Walters 2017; Jacques 2022
EB-04Restrictive eligibility criteria and protocol complexity Grade B
Effect
Negative; more eligibility criteria associated with accrual failure (p=0.013), 21.5% of cancer patients ineligible for an available trial, procedure counts rising 6.5 to 10.5% a year, and tissue sample required OR 1.26 with a CI including 1.
What helped
CTTI framework recommends limiting complexity and realistic eligibility (not quantified).
What did not
not found
Sources
Carlisle 2015; Unger 2019; Getz 2008; Getz 2018; Bennette 2016
Watched by
Screen failure above the study's (KRI); Ineligible patients randomised (QTL)
EB-17Follow-up burden and duration Grade C
Effect
Negative; trials with final follow-up beyond 18 months recruit at 0.71 per centre per month against 1.29 for follow-up within a month (p=0.054); time commitment is a key deterrent in the qualitative synthesis.
What helped
Reducing visit burden (CTTI, not quantified).
What did not
not found
Sources
Jacques 2022; Houghton 2020
Watched by
Missing primary endpoint data (QTL); Lost to follow-up or withdrew consent (QTL)
EB-26Common solid tumours, radiation protocols and multi-condition oncology trials Grade A
Effect
Low accrual OR 2.32 for prostate, breast, lung and colon trials against liquid or rare solid tumours; OR 1.81 radiation; OR 1.98 more than one condition; OR 0.57 targeted therapy; OR 0.34 investigational new drug (NCTN).
What helped
Not an intervention; use as oncology priors.
What did not
not found
Sources
Bennette 2016
PB-02Eligibility criteria exclude patients (comorbidity, age, performance status, language) Grade A
Effect
21.5% (10.9 to 34.6) of patients with an open trial are ineligible; any comorbidity cuts participation odds to 0.76; 81.3% of high-impact RCTs exclude common conditions; 19% of US trials require English.
What helped
Broadening criteria: dropping the comorbidity restrictions ASCO recommends removing could add up to 6,317 registrations a year; translation widens the pool.
What did not
not found
Sources
Unger 2019 JNCI; Unger 2019 JAMA Oncol; Van Spall 2007; Muthukumar 2021
Watched by
Screen failure above the study's (KRI); Ineligible patients randomised (QTL)
PB-10Older adults under-enrolled Grade A
Effect
People aged 65 and over were 25% of trial entrants against 63% of cancer patients; trial median age 6.49 years below the population; 70 and over are 24% of FDA-registered trial participants against 42% of the cancer population.
What helped
Coverage policy raised 65 and over accrual (Unger 2006); broader eligibility and fewer performance-status cut-offs narrow the gap (Ludmir 2019).
What did not
Physician geriatric education, cluster RCT across 126 institutions, no effect (Kimmick 2005).
Sources
Hutchins 1999; Ludmir 2019; Sedrak 2021; FDA Snapshots 2024
PD-01Restrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status) Grade A
Effect
Negative; eligible pool ×0.48 to 0.53 against broadened criteria, with the hazard ratio unchanged or better.
What helped
ASCO-Friends modernised criteria and the FDA 2020 to 2026 guidances; data-driven criteria; adoption of 54 to 93% by criterion in NCI CTEP protocols.
What did not
Laboratory and washout exclusions carried forward unchanged across phases and years.
Sources
Harvey 2021; Liu 2021; Kim 2017 and 20212; Unger 2019
Watched by
Screen failure above the study's (KRI); Ineligible patients randomised (QTL)
PD-02Number of eligibility criteria and complexity growth Grade B
Effect
Negative; more criteria independently associated with poor accrual (p = 0.013); complex trials randomise 59% of screened against about 75%.
What helped
Upstream protocol feasibility review and benchmarking against Tufts norms.
What did not
not found
Sources
Carlisle 2015; Getz 2014; Getz 2023
Watched by
Screen failure above the study's (KRI); Important protocol deviations (KRI); Ineligible patients randomised (QTL)
PD-03Procedural and visit burden (visits, blood draws, questionnaires) Grade B
Effect
Negative; burden score predicts screen failure, trial duration, and amendments (p < 0.01); oncology plans 29 visits against 16.
What helped
Score burden at design; prune non-core procedures, which are 22 to 25% of all procedures.
What did not
Sites rate decentralised trials as more burdensome for patient-facing procedures.
Sources
Smith 2021; Dirks 2025; Getz 2023
Watched by
Important protocol deviations (KRI); Missing primary endpoint data (QTL); Lost to follow-up or withdrew consent (QTL); Stopped study treatment early (QTL)
PD-04Substantial protocol amendments Grade B
Effect
Negative; 76% of protocols amended, 3.3 each, 260 days to implement, 215 days of version mismatch, enrolment against plan reduced; $141,000 to $535,000 each.
What helped
Governance review before approval, since about 40% of amendments occur before first patient first dose.
What did not
Amendments raise screening volume but not enrolment against plan.
Sources
Getz 2016; Getz 2024; Botto 2024; Getz 2014
PD-05Placebo or no-added-treatment control arm Grade B
Effect
Negative; willingness 30% against 39%; acceptance 60.5% against 80.6%.
What helped
All-active arms; add-on designs; equipoise-focused recruiter training through the QRI.
What did not
not found
Sources
Welton 1999; Jenkins 2000; Mills 2006; Uzzan 2023
Watched by
Stopped study treatment early (QTL)
PD-06Blinded placebo-controlled against open design Grade A
Effect
Negative for blinding; an open design adds 10 percentage points (95% CI 7 to 13), high certainty.
What helped
Open or PROBE design where scientifically acceptable.
What did not
User-tested information leaflets added 1 point, no effect.
Sources
Treweek 2018
PD-07Unequal randomisation ratio used to aid recruitment Grade C
Effect
Unclear; 57% of trials give no rationale and no recruitment benefit is documented.
What helped
not found
What did not
The claimed recruitment benefit is unproven.
Sources
Dumville 2006
PD-09Washout periods and concomitant-medication exclusions Grade C
Effect
Negative and qualitative; IBD patients deterred; criteria often arbitrary.
What helped
Remove arbitrary washouts, as the FDA final guidance of July 2026 requires.
What did not
not found
Sources
Harvey 2021 washout group; Liu 2021; Uzzan 2023
PD-10Run-in period before randomisation Grade C
Effect
Negative for randomised yield; narrows the population and overstates benefit.
What helped
Use only where there is a scientific need.
What did not
not found
Sources
Pablos-Méndez 1998
PD-11Advanced line of therapy Grade B
Effect
Negative; 40 to 57% of first-line patients reach second line and attrition is about 60% per line (pool evidence grade B; per-site rate evidence grade D).
What helped
Allow any number of prior lines where scientifically justified.
What did not
not found
Sources
Ran 2025; Sheffield 2026; Lee 2026; Schoenfeld 2025; Osarogiagbon 2021
PD-12Biomarker-selected population with low marker prevalence Grade B
Effect
Negative; 37.6% actionable and 17.8% assigned in NCI-MATCH; 39 to 70% amyloid-negative at screening; MASH screen failure 56%.
What helped
Central screening at scale (1,117 sites); EHR and registry pre-screening.
What did not
not found
Sources
Flaherty 2020; Sevigny 2016; Sperling 2020; Souza 2025
PD-15Comorbidity exclusions Grade B
Effect
Negative; 65.6% of cancer patients have at least one comorbidity; participation OR 0.76.
What helped
Remove ASCO-flagged comorbidity restrictions, simulated to add up to 6,317 US registrations a year.
What did not
not found
Sources
Unger 2019 JAMA Oncology
Watched by
Ineligible patients randomised (QTL)
PD-16Consent document length and reading level Grade C
Effect
Unclear for enrolment; mean 10.8 pages and Gunning Fog grade 11.9.
What helped
Shorter, plain-language materials improve comprehension.
What did not
User-tested leaflets did not change recruitment.
Sources
Sharp 2004; Beardsley 2007
Watched by
Consent findings (KRI)
PD-17Active comparator (against placebo) in registry data Grade B
Effect
Negative association only; poor accrual 23% against 16%.
What helped
not found
What did not
not found
Sources
Carlisle 2015
PD-20Decentralised elements Grade C
Effect
Unclear; modelled value only; sites split on whether they add or remove burden.
What helped
Hybrid elements for follow-up visits.
What did not
A fully remote trial under-recruited despite a very large outreach funnel.
Sources
FDA 2024; DiMasi 2023; Nassif 2023; Florez 2024
PM-05Screen failure is high and varies widely by therapeutic area Grade A
Effect
Cuts randomised patients per screened: 36.3% overall and rising, CNS 57%, rare disease 81% ineligible, inflammatory bowel disease 43% to 53%, heart failure outcome trials 42% to 48%, COPD 37% to 42%, oncology 34% to 51%.
What helped
not found
What did not
Protocol planning assumptions of 10% for asthma and 20% for COPD were exceeded two to four times over in three COPD Phase III programmes.
Sources
Tufts CSDD 2019; Tufts CSDD 2012; IBD trials analysis 2025; UCSD 2022; Tata 2023; DAPA-HF and EMPEROR-Reduced dispositions2; COPD letter
Watched by
Screen failure above the study's (KRI)
S-14Protocol amendments before and after activation Grade B
Effect
Negative on time: 24% of studies amended before activation, a 4 to 6 week delay typical and 10 weeks or more for about 20% of centres, 260 days to implement an amendment, and 82% of Phase III protocols amended.
What helped
Finalise the protocol before feasibility. Take site input on design (46% of sites ask for it).
What did not
not found
Sources
Clinical Trial Vanguard 2024; AACI 2026
S-24Protocol complexity and site burden Grade B
Effect
Negative: procedures up 40.6%, sites per protocol up 60.1%, and enrolment duration up 36.9% (2010 to 2020); 70% of site staff say trials are much harder; about one-third of data collected is non-core.
What helped
Remove non-core data and procedures. Take site input on design.
What did not
not found
Sources
Clinical Trial Vanguard 2024; WCG 2024; Tufts CSDD 2022; PharmaVoice 2025
Watched by
Important protocol deviations (KRI)
SH-03Therapeutic-area sensitivity to a pandemic Grade A
Effect
Oncology least hit (April −41%, baseline by June); cardiovascular −97%, respiratory −92%, endocrine −82%, dermatology −74% in April; control and prevention trials −73% against treatment trials −29% (SWOG).
What helped
Prioritise trials where treatment cannot be deferred.
What did not
Deferrable trials (prevention, dermatology) stayed depressed for months.
Sources
Medidata 20202; Unger et al. 2020 and 20212
SH-20Comparator or backbone drug shortage (platinum 2023) Grade B
Effect
43% of centres reported trial impact in 2024, 58% of those with reduced enrolment; NCI said 174 of 608 trials might be affected.
What helped
Substitution by amendment; central allocation of scarce supply.
What did not
Opening new trials dependent on shortage drugs.
Sources
CNN 2023; OncLive 2024; ASCO Post 2024
Watched by
Study drug at the site (KRI); Stopped study treatment early (QTL)
SH-29Standard-of-care change Grade B
Effect
11% of non-data terminations on ClinicalTrials.gov came from external information or product withdrawal.
What helped
Protocol amendment of the comparator.
What did not
not found
Sources
Williams et al. 2015

Site

EB-02Competing trials for the same patients Grade A
Effect
Negative; OR 1.88 (95% CI 1.32 to 2.68) for low accrual per additional competing trial per 10,000 eligible patients per year, with low-accrual trials facing a median 4.4 against 2.9 competing trials.
What helped
Not tested as an intervention; Bennette's model identified a top-decile risk group with 52% low accrual, usable for site and country selection.
What did not
not found
Sources
Bennette 2016; Schroen 2011
PB-01No trial open at the patient's institution (structural access) Grade A
Effect
Removes 55.6% (95% CI 43.7 to 67.3) of cancer patients before any offer; community sites enrol 7.0% of patients against 15.9% at academic centres.
What helped
Opening trials at community sites; EHR alerts to find eligible patients multiplied referrals by 10.44 at one site (Embi 2005).
What did not
Mass media alone has no low-bias evidence (Cochrane).
Sources
Unger 2019 JNCI
PD-08Lack of clinician equipoise and physician gatekeeping Grade B
Effect
Negative; 73% of non-entering surgeons cite the doctor-patient relationship; decliners prefer doctor choice 54% against 39%; comorbid patients are less often offered trials (OR 0.82).
What helped
The QRI supported five RCTs to target, with randomisation rates up in three.
What did not
QRI-Two performed less well in 6 of 14 start-up trials.
Sources
Taylor 1984; Jenkins 2013; Unger 2019; Rooshenas 2019
PM-02Academic and hospital sites, and sites new to the sponsor, take longer to activate Grade B
Effect
Delays activation by months: 8.1 to 9.4 months for academic medical centres against 4.4 to 4.8 for independent sites, 12.9 against 7.9 months from pre-study visit to first patient, and 35.6 weeks for new sites against 25.7 for repeat sites.
What helped
not found
What did not
not found
Sources
WCG Data Intelligence 2023 to 2025; Tufts CSDD 2012; Tufts CSDD 2018
PM-07Site recruitment rates are highly heterogeneous within a trial Grade B
Effect
Widens the forecast band: gamma shape 1.75 to 2.15 in myeloma trials (coefficient of variation about 0.7), a simulation convention of CV 1.2 (shape about 0.69), and a fit of about 0.4 to 0.5 to Phesi's cancer-trial distribution.
What helped
not found
What did not
not found
Sources
Minois 2017; Urbas 2020; Anisimov 2024; Phesi 2023
PM-08A large share of sites enrol nobody or a single patient Grade A
Effect
Reduces effective sites: 11% of sites enrolled none and 37% under-enrolled in 2008 to 2010; in cancer trials about 21% of all sites enrol none and 19% of enrolling sites enrol one, while the top 16% supply 54% of patients.
What helped
not found; Phesi's implied response of fewer, better-selected sites has no outcome data.
What did not
not found
Sources
Tufts CSDD 2012; Tufts CSDD press release 2013; Phesi 2023
Watched by
The study's KPIs
RW-03Mandatory audio-visual consent for all participants Grade C
Effect
Negative for enrolment speed and investigator willingness; the magnitude was not measured.
What helped
Narrowing the requirement to vulnerable participants in trials of new chemical or molecular entities (31 July 2015).
What did not
The universal requirement (November 2013 to July 2015).
Sources
Roy Chaudhury and Mehta 2016; Barnes et al. 2018
Watched by
Consent findings (KRI)
S-01Non-enrolling activated sites Grade A
Effect
Negative: 11% of activated sites enrol nobody industry-wide (2008 to 2010), zero-patient sites equal 27% of enrolling sites in recent oncology trials, the median benchmark site had zero completers, and the share has not changed in 20 years.
What helped
Plan for non-performers explicitly (Phesi: about 150 sites to get 120 enrolling). One sponsor cut non-delivering sites from about a third to 10% with dedicated start-up staff.
What did not
Treating sites as interchangeable. Extensions alone did not raise the chance of reaching target.
Sources
Tufts CSDD 2013; Silverman 2013; Getz 2012; Phesi 2023; Smith and Getz 2026; Miseta 2017
Watched by
The study's KPIs
S-02Under-enrolling sites Grade A
Effect
Negative: 37% of sites under-enrol and 48% miss target, enrolling sites average 85% of target, and benchmark trials enrol 33% below plan.
What helped
Pre-trial accrual assessment (67% versus 47% sufficient accrual, p = 0.08). Early milestone monitoring.
What did not
Relying on self-reported feasibility questionnaires.
Sources
Tufts CSDD 2013; Getz 2012; Smith and Getz 2026; WCG 2018
Watched by
The study's KPIs
S-04Past performance as a predictor Grade B
Effect
Positive but modest: Spearman 0.13 to 0.16 for historical rate alone and 0.37 to 0.46 with patient-volume data; well-performing sites have a 70% higher chance of out-performing; trial-manager predictions reach 82% sensitivity but 32% specificity.
What helped
Combine historical rate with real-world patient volume, referral flow, and research experience. Guided prediction forms with red flags.
What did not
Historical performance alone. Unguided judgement after the initiation visit.
Sources
Getz 2011; Hulstaert 2024; Bruhn 2019; Yang 2018; Ninh 2026
S-05New-to-sponsor site Grade B
Effect
Negative on time: 28 to 30% of sites are new to the sponsor and initiation takes about 10 weeks longer; sites with 6 to 10 trials' experience are more likely to hit target; no measured rate penalty.
What helped
Repeat-site preference where the patient pool allows. Master agreements and central IRB.
What did not
not found
Sources
Getz 2011; WCG 2018; Getz 2016; Miseta 2017
Watched by
Important protocol deviations (KRI)
S-06Site type: activation speed Grade A
Effect
Negative for academic and hospital sites: median 8.1 months versus 4.4 months for independent sites; 9% versus 54% start within 60 days; 21%, 34%, and 80% within 60 days for AMCs, hospital systems, and investigative sites.
What helped
Standardised start-up workflow with a site navigator (133 versus 277 days). Master contracts. UK National Contract Value Review (305 to 194 days).
What did not
Sequential review layers. Pre-activation amendments, which add 4 to 6 weeks each.
Sources
Smith (WCG) 2024; Advarra 2020; WCG 2025; Dilts and Sandler 2006
Watched by
Site activation overdue (KRI); The study's KPIs
S-07Site type: enrolment rate Grade C
Effect
Positive for research-focused sites: 41% better enrollers than practice-focused sites (72 protocols); in-network investigators about 25% more; network sites may have an advantage on a small sample.
What helped
Select sites with dedicated research infrastructure and a recruitment plan.
What did not
not found
Sources
Getz 2011; Dirks, Chambers, and Getz 2026; Yang 2018
S-08Investigator attrition and one-and-done investigators Grade C
Effect
Negative on the site pool: 54% of single-filing PIs were one-and-done (6.9% response rate) against an alternative estimate under 20%; about 40% of US investigators quit yearly in the 2000s; WCG reports 66% take part in a single trial and a sharp fall in unique US investigators from 2020 to 2024 (vendor data).
What helped
Link willing investigators to sponsors (44% wanted another trial but none was offered). Reduce workload, time, and reporting burden.
What did not
not found
Sources
Getz 2011; Ivsin 2024; Corneli 2017; Smith (WCG) 2024; WCG 2024
S-09Coordinator turnover Grade B
Effect
Negative: typical turnover of 10 to 37% rose to 35 to 61% in 2022, Duke's voluntary rate runs 15 to 19%, 51% of sites reported under 10% in 2024, SCRS estimates 6 to 12 months to get a study back on track, and a vendor reports a six-week enrolment pause and 3 to 7 lost enrolments per affected study.
What helped
Study continuity plans, renegotiated budgets, flexible schedules, and career paths. Capacity-pod staffing (vendor claim, 41% less disruption).
What did not
Matching sponsor and CRO salaries, which sites say they cannot do.
Sources
WCG 2024; Stroo 2025; SCRS 2023; Bourne 2024; Clinitiative 2026; Zoster Eye Disease Study 2024
Watched by
Data entry lag (KRI); Queries open over 30 days (KRI)
S-11Site capacity saturation Grade B
Effect
Negative on available capacity: 45 to 47% of sites say challenges restrict new-study participation and 50% of US sites agreed to fewer studies in 2024.
What helped
Fund pre-screening, screen-failure, and start-up costs (site-advocated; no measured enrolment effect).
What did not
not found
Sources
WCG 2024; WCG 2025
Watched by
Data entry lag (KRI)
S-21Competing trials Grade B
Effect
Negative when the eligible pool is scarce: OR 1.88 (1.32 to 2.68) for low accrual per competing trial per 10,000 eligible patients per year; no effect when the pool is large; 3,042 immuno-oncology trials sought 577,076 patients.
What helped
Redirect referrals to non-overlapping sites and re-engage the PI (anecdotal). Choose indications and regions with slack.
What did not
Adding sites into the same saturated pool.
Sources
Bennette 2016; Hutchinson 2022; Tang 2018; ClinOops 2026
S-26Sites declining new studies for lack of capacity Grade C
Effect
Negative: 45% of sites say their current challenges restrict their ability to take on new studies (49% of larger sites), and 16% report participating in fewer studies.
What helped
Sites report hiring (34%), staff and PI training (33%), technology (26%), and partnering with clinical services companies (19%); no outcome was measured.
What did not
not found
Sources
WCG 2025 Site Challenges Report, 611 sites, self-reported
S-30Fewer physicians willing to be investigators Grade C
Effect
Negative: 25% of sites report fewer physicians interested in or available to be principal investigators over the past year, against 19% reporting more.
What helped
not found
What did not
not found
Sources
WCG 2025 Site Challenges Report, 611 sites, self-reported
SH-04Research-staff redeployment and burnout (long tail) Grade B
Effect
Headwind for 2 to 3 years; coordinator shortages at 64.6% of sites; 80% of cancer centres with activation delays and 64% with declining accrual.
What helped
Flexible working and retention measures; AACI turnover fell 29% from 2021 to 2022.
What did not
Hiring inexperienced coordinators; a six-month cost per replacement is claimed by SCRS (anecdotal, no dataset).
Sources
Advarra 2025; AACI 2023; Sun et al. 2023
SH-07Proximity to the fighting within a country at war Grade B
Effect
Steep gradient: the east and north of Ukraine were hit while Kyiv was near normal within two months; about half of sites kept recruiting.
What helped
Move patients west inside the country, which GlobalData calls more typical than cross-border transfer.
What did not
Assuming a nationwide shutdown.
Sources
Clinical Research News 2022; Clinical Trials Arena 2022; Phesi via Lab News 2022
SH-11Major earthquake in a site region Grade C
Effect
Headwind, probably near-total in destroyed provinces (three main hospitals destroyed in Hatay); health staff partly back on duty within a day.
What helped
Transfer to unaffected cities (the dashboard's assumption; untested).
What did not
not found
Sources
IFRC 2023
SH-30Competing trials at a site Grade D
Effect
Not found; practitioner belief that concurrent trials dilute per-trial enrolment is widespread but anecdotal.
What helped
not found
What did not
not found
Sources
not found (practitioner belief, anecdotal)

Patient

EB-19Retention and dropout Grade A
Effect
Median retention 88 to 89% in UK public trials; 17% dropout per industry trial; 18% of randomised patients dropped out in the 1998 to 2012 funnel benchmark; dropouts more often found consent forms difficult (35% against 16%) and visits stressful (38% against 16%).
What helped
Moderate certainty: monetary reward with a reminder or pre-notification; self-sampling kits; a pen at recruitment.
What did not
Adding a diary to follow-up (reduces retention, moderate); no high-certainty retention strategy exists.
Sources
Walters 2017; Jacques 2022; Getz 2012; Advarra infographic; Gillies 2021
Watched by
Missing primary endpoint data (QTL); Lost to follow-up or withdrew consent (QTL)
PB-16Digital divide in decentralised designs Grade B
Effect
Home broadband is 71% at 65 and over, 57% under $30,000, and 72% in rural areas; virtual samples are younger.
What helped
Hybrid designs with device loan and phone support; 12% of older participants needed it and retention was 84% (Hewston 2026).
What did not
Decentralised-only designs for older groups, direction only (Goodson 2022; Coyle 2022).
Sources
Pew 2026; Moseson 2020; Hewston 2026
PD-13Rare or orphan population Grade B
Effect
Negative; 27 against 64 sites; enrolment 603 against 444 days; completion 50.8% against 72.5%; early termination 13.7% against 6.3%.
What helped
Expert-centre networks; single-arm and open designs; natural-history controls.
What did not
not found
Sources
Getz 2023; Bell 2014
SH-14Displacement-driven loss to follow-up Grade B
Effect
Non-participation odds +54% for evacuation outside the municipality and +40% outside the prefecture (Fukushima cohort).
What helped
Multiple contact channels; relationship-based retention (TRACER).
What did not
Rigid visit windows.
Sources
Yamamoto et al. 2022
Watched by
Missing primary endpoint data (QTL); Lost to follow-up or withdrew consent (QTL)

Sponsor, CRO and model

EB-18Protocol amendments Grade B
Effect
Negative; 57% of protocols had at least one substantial amendment, 45% avoidable; amended protocols recruited longer and enrolled fewer than planned; median direct cost $535,000 in Phase III; over 40% amend before first patient visit, delaying about four months (secondary).
What helped
Protocol governance and simplification (not quantified).
What did not
not found
Sources
Getz 2016; Getz 2011 via Fogel 2018
EB-23Patient and public involvement in design Grade B
Effect
Positive; PPI interventions associated with higher enrolment (OR 1.16, 1.01 to 1.34), larger with lived-experience involvement (OR 3.14 against 1.07, exploratory); PRioRiTy question 3 asks exactly this.
What helped
Involving people with lived experience of the condition in planning.
What did not
Retention effect inconclusive (OR 1.16, 0.33 to 4.14).
Sources
Crocker 2018; Healy 2018
FM-06Sites needed derived by a deterministic rule with no confidence level Grade B
Effect
Target divided by expected patients per site plans to roughly an even chance of finishing on time; Carter's unconditional estimate was 18 months against a simulated 23.2 months (SD 1.0), and the probabilistic site count rises from 40 to 49 as confidence rises from 0.5 to 0.9.
What helped
The least N with P(T(n, N) ≤ T) ≥ p via the negative binomial identity, the normal criterion, or simulation to a threshold.
What did not
Expected-value site counts such as Shipes's 197 sites and Carter's unconditional 18 months.
Sources
Carter, Sonne, and Brady 2005 [23]; Shipes et al. 2023 [16]; Anisimov and Austin 2022 [5]
PB-12Racial and ethnic under-representation Grade A
Effect
Black patients were 3.1% of participants in US oncology approval trials (22% of expected); only 43% of US trials report race; industry trials have OR 0.69 for minority share; willingness when offered is equal (58.4% against 55.1%).
What helped
Navigation raised the African American share from 9% to 16% at one centre (Fouad 2016); enrolment targets and site redirection moved COVE's Black share from about 7% to 10.2% and gave PREVENT-19 21.5% Hispanic participants; trained same-background lay recruiters helped in one small study.
What did not
Single-level interventions alone (Hamel 2016); untargeted social media advertising skews to young white women (Whitaker 2017).
Sources
Loree 2019; Turner 2022; Unger 2021
Watched by
Enrolment against the diversity plan (KRI)
PD-18No patient and public involvement in design Grade A
Effect
Positive when present; enrolment OR 1.16 (1.01 to 1.34); lived-experience involvement OR 3.14, exploratory.
What helped
Patient and public involvement in protocol design.
What did not
Retention was not improved (OR 1.16, 0.33 to 4.14).
Sources
Crocker 2018
PD-21No upstream protocol feasibility review Grade B
Effect
Negative; 23 to 45% of amendments avoidable and about 40% occur before first patient first dose.
What helped
Cross-functional governance review; the CTTI three-area framework; critical-to-quality factors at planning.
What did not
not found
Sources
Getz 2014, 2016, and 202423; Huang 2018; ICH E8(R1)
PD-23Recruitment-rate expectations set too high Grade A
Effect
Negative; only 56% of UK HTA trials reach target; median 0.92 participants per centre per month.
What helped
Plan with 90% power and realistic rates; pilot first.
What did not
Extensions do not fix under-recruitment.
Sources
Walters 2017; Sully 2013; McDonald 2006; Kasenda 2014
Watched by
The study's KPIs
PM-14Under-performing sites inflate cost per patient Grade B
Effect
Raises cost: on Phesi's assumptions of $40,000 to activate a site and $3,000 a month, a single-patient site over 30 months costs about $130,000 per patient against about $14,000 at the best sites; the median pivotal trial costs $41,413 per patient, oncology $100,271.
What helped
not found
What did not
not found
Sources
Phesi 2023; Moore 2020; Sertkaya 2016
S-10CRA turnover and monitoring continuity Grade C
Effect
Negative, unquantified for enrolment: CRA turnover 28 to 32% in 2021 to 2022, nine months to proficiency, and sites deprioritise studies when the sponsor is absent (qualitative).
What helped
Mentoring, flexible schedules, and pay.
What did not
not found
Sources
Parrish and Minns 2025; Lamberti 2022
S-12Start-up: contracts and budgets Grade A
Effect
Negative on time: the top delay cause for 73% of sites, 63% say fee negotiation holds activation, identification to initiation has sat at about 31 weeks for a decade, and 40% of engaged North American sites never activate.
What helped
Master agreements, standard clauses, and national model contracts (UK NCVR cut 111 days). Dedicated start-up staff.
What did not
Slow sponsor budget responses, reported by 50% of sites.
Sources
WCG 2018; Miseta 2017; Clinical Trial Vanguard 2024; Advarra 2020; WCG 2025
Watched by
Site activation overdue (KRI); The study's KPIs
S-15Sequential or late site activation Grade B
Effect
Negative: only 6% of trials activate 50 or more sites within 100 days, the average Site Effectiveness Index is about 50%, linear Phase II to III site scaling cost 5 to 21 months, 30% of sites activated in the last six months were mostly non-performing, and sites starting more than 5 months after the first patient supplied under 10% of enrolment in 11 of 14 large trials.
What helped
Staged 70/30 activation based on first-batch performance. Batch activation with surplus sites planned for non-performers.
What did not
Proportional site additions. Extensions. Adding sites many months into enrolment.
Sources
Clinical Trial Vanguard 2024; Li (Phesi) 2018; Haidich and Ioannidis 2003; Getz, Smith, Peachey, and Li 2022
Watched by
The study's KPIs
S-16Feasibility over-optimism Grade A
Effect
Negative: 31 to 56% of trials reach target, 45 to 53% are extended, 81.5% of NCI trials miss the projected accrual window, regional delivery runs 43 to 104% of forecast, and one pilot delivered 44% of plan.
What helped
Internal pilots with monthly re-forecast from screening logs. Pre-trial accrual assessment. Stop or go milestones.
What did not
Unverified questionnaires. Extensions without any change in approach.
Sources
Altair 2015; McDonald 2006; Sully 2013; Walters 2017; Bertram 2019; Cheng 2011
Watched by
The study's KPIs
S-17Slow site payment and holdbacks Grade B
Effect
Negative, self-reported for enrolment: 83% of sites want payment within 30 days, 37% of North American sites were paid after 90 days (2012), 23% of sites have 31 to 40% of invoices over 90 days late, one-third have receivables over 90 days, 50% have three months or less of cash, and sites say slow payment reduces screening and enrolment effort.
What helped
Monthly electronic payment, no holdback, and automated pass-through invoicing (site-preferred; effect self-reported).
What did not
Quarterly payment and 10 to 14% holdbacks.
Sources
Miseta 2016; SCRS 2023 Site Landscape; Scout 2025; Bourne 2024; SCRS and Greenphire 2017
S-18Technology burden Grade B
Effect
Negative on site time, unquantified for enrolment: 60% of sites use 20 or more systems daily, about 10 to 12 applications per site in 2015, 46% say too many separate technologies and 74% cite login tracking (2020), 40% of sites spend 5 to 15 hours per month per study on unpaid training, and 19% rank sponsor technology a top challenge.
What helped
Accept site-preferred systems. Consistent technology across a sponsor's studies. Paid training.
What did not
not found
Sources
WCG 2024; SCRS 2023 Site Landscape; Bechtel 2024; Florence 2024; SCRS 2020
Watched by
Data entry lag (KRI); Queries open over 30 days (KRI)
S-22Rescue by adding sites Grade B
Effect
Weak to negative: extensions are no more likely to succeed, timelines nearly double, STICH grew from 32 to 171 sites with 44 zero-enrollers, late-starter sites supplied under 10% of enrolment in 11 of 14 large trials, and new sites take 4 to 8 months to activate plus about 1 to 3 months to first patient.
What helped
Early decision. Staged activation. Poisson-gamma computation of the sites needed at a chosen confidence.
What did not
Late, proportional site additions. Adding sites many months after the start.
Sources
Tufts CSDD 2013; Smith (WCG) 2024; CRIO 2026; Sully 2013; Fogel 2018; Li (Phesi) 2018; Haidich and Ioannidis 2003
Watched by
The study's KPIs
S-28Late or complicated payments to sites outside the US Grade C
Effect
Negative: ex-US sites name trial payments their top challenge (30%, against 17% of US sites).
What helped
not found; WCG recommends prompt and accurate payments, and SCRS sites ask for payment within 30 days (section 3), but no recruitment outcome is measured.
What did not
not found
Sources
WCG 2025 Site Challenges Report, 611 sites, self-reported

Country and policy

PM-01Site start-up time varies by country and is the longest step in a trial Grade A
Effect
Delays first patient: site start-up runs 253 days in the US and 339 days in the EEA for oncology, UK medians have ranged from 247 to 122 days by cohort, Spain's hospitals reach 124 to 139 days, and Polish companies report 96 to 251 days.
What helped
Spain's non-negotiable national model contracts cut contracting from 117 to 90 days. The UK's National Contract Value Review cut costing submission to first consent from 305 to 194 days, HRA approval fell from 113 to 74 days, and the KPI programme took the CTA-to-first-participant median from 169 to 122 days.
What did not
The UK drifted from 222 days in 2018 to 247 in 2020 before the reforms, and Spain's set-up slowed by 25% after 2018.
Sources
IQVIA for EFPIA 2024; ABPI 2022; GOV.UK KPIs 2026; Farmaindustria BEST via Redacción Médica; Infarma 2021
Watched by
Site activation overdue (KRI); The study's KPIs
PM-03The US activates its first site quickly but scales its site fleet slowly Grade B
Effect
Delays the bulk of US sites: first US site 124 days after protocol approval against 308 ex-US, but 309 days to activate 75% of US sites against 34 to 126 days in other regions, and 93 days to first patient against 43 to 60.
What helped
not found
What did not
not found
Sources
Friends of Cancer Research 2026
Watched by
Site activation overdue (KRI)
PM-04Start-up time for India and Turkey is unmeasured Grade C
Effect
Unknown magnitude: only statutory clocks (India 90 working days, Turkey 12 plus 22 business days) and reconstructed 2014 to 2015 CRO bars putting Turkey at about 336 days and India at 252 days from site identified to initiated.
What helped
India's NDCT Rules 2019 cut the statutory clock from 180 to 90 working days, with no published measurement of the effect on time to first patient.
What did not
India's 2013 regulatory tightening without a transition collapsed approvals from 500 a year to about 12 to 17 in early 2013.
Sources
IJPER 2019; PMC8694703; Mondaq; Infarma 2021 Fig 15
Watched by
Site activation overdue (KRI)
POL-02Regulator assessment backlog Grade A
Effect
Negative: UK assessment took 118.9 days in July 2023 against a 30-day target, and approval outside the combined route took 90 days in 2021 against 61 days inside it.
What helped
Triage, staff redeployment, contracted assessors, and ring-fenced funding (£10m) restored a 28-day average within months; the combined single-route review reached a 29-day median in 2025.
What did not
Under-resourcing was left in place for a year, and scientific advice moved to written-only, so a capacity gap persists.
Sources
ABPI 2024; O'Shaughnessy review 2023; British Journal of Cancer 2026
POL-03Fragmented, negotiated costing and contracting Grade A
Effect
Negative: UK costing submission to first consent took 305 days before the NCVR; Spanish contracting took 117 days in 2016; Germany's decline is attributed to extensive negotiation times.
What helped
Mandated national pricing and non-negotiable model contracts: UK 305 to 194 days (minus 36 per cent); Spain 117 to 90 days; a standardised contract mandated by NHS England from September 2025.
What did not
Voluntary adoption: 41 per cent of trusts committed and 53 per cent of providers accepted costings; sites still request top-ups after national costing.
Sources
ABPI 2022; HRA 2023; Health and Care Research Wales 2023; IQVIA for EFPIA 2024 (Germany attribution grade C)
POL-15Regional regulatory transition friction (EU CTR and CTIS) Grade A
Effect
Negative to neutral: the EEA share of global starts fell from 18 to 9 per cent (2013 to 2023) through the transition; 40.8 per cent of trials recruit within 200 days of application; transitions surged at the 2024 to 2025 deadline.
What helped
A single EU decision with a 98.4 per cent authorisation rate; ACT EU targets; the CTIS task force; FAST-EU.
What did not
The CTR alone did not restore share, and CTIS usability complaints persist.
Sources
IQVIA for EFPIA 2024; ACT EU 2025; ACT EU KPIs 2026
Watched by
Site activation overdue (KRI)
POL-20Ethics-committee structure (random CPP allocation, 40 Italian territorial committees, a central Polish committee, Denmark's timeliness) Grade B
Effect
Mixed: Denmark decides 100 per cent of submissions within CTR timelines; the effects of random CPP allocation in France, Italy's territorial committees, and Poland's central committee are not quantified.
What helped
A single national opinion (Spain, UK).
What did not
not found
Sources
IQVIA for EFPIA 2024; Wikipedia CPP; AIFA; Danish Medicines Agency 2026 (Denmark grade B, others grade D)
RW-05Ethics-committee re-registration or re-constitution that cuts review capacity (India 2013; Turkey 2024) Grade B
Effect
Negative for start-up: Turkey's committees fell from 145 to 49 and ethics applications to TİTCK fell 44% (911 to 510) in 2024, but the resulting activation delay was not measured.
What helped
Transitional continuity, online meetings, and deferred filings, as in TİTCK's 2023 earthquake playbook.
What did not
not found
Sources
Roy Chaudhury and Mehta 2016; TİTCK activity reports 2023–202523
Watched by
Site activation overdue (KRI)
RW-07Currency crisis with a fixed pharmaceutical exchange rate (Turkey 2018–2026) Grade D
Effect
Negative for medicine supply (645 products short in November 2021, cancer and antibiotic shortages in 2024, goserelin suspended in 2025; supply grade B) and plausibly for site budgets, but no trial-level effect was measured.
What helped
Periodic increases in the pharmaceutical euro rate (2023, 2024, 2026).
What did not
Holding the rate at 50–60% of the market rate; individual import requests proved slow and costly.
Sources
Hasanzadeh 2024; Farooq 2021; Turkish Minute 2026; Koyuncu et al. 2020
Watched by
Study drug at the site (KRI); Stopped study treatment early (QTL)
S-13Ethics and regulatory cycle by country Grade B
Effect
Country-specific lag: UK median 122 days from application to first participant (2025) down from 247 (2020), with 56% opening within 60 days of approval; India 90 (or 30 deemed) working days statutory; Turkey 7 and 12 working days for bioequivalence studies statutory; Poland under EU CTR 16 + 45 + 5 days statutory; Spain 197 days (2020); practical durations outside the UK not found.
What helped
Combined review (61 versus 90 days in the UK). Single national costing. Deemed approval in India.
What did not
not found
Sources
O'Shaughnessy 2023; UK KPIs 2026; Wardyński 2023; Esin 2023; India NDCT Rules 2019
Watched by
Site activation overdue (KRI)
SH-01Pandemic wave, first national lockdown Grade A
Effect
Headwind: new patients per site fell 59% globally in the trough month against the 2019 baseline (UK −87%, India −98%, US −45%, Spain −60%, France −77%, Germany −68%).
What helped
Remote visits, direct-to-patient IMP, pausing non-essential screening, and protecting enrolled patients; oncology continued.
What did not
Remote SDV (regulators diverged and sponsors reverted within months); the UK's non-COVID triage cost 44% of commercial recruitment.
Sources
Medidata Release 6.0 and 9.0, 2020; Unger et al. 2020
SH-02Pandemic recovery and second waves Grade A
Effect
Partial recovery over 3 to 5 months with reversals: global −10% in July and −20% in August 2020; UK −40%, India −71%, US −22%, Spain +25% in August.
What helped
Phased restart frameworks (NIHR levels); reducing recruitment before pausing.
What did not
Staff attrition prolonged recovery; the winter wave cut SWOG enrolment 2% a week.
Sources
Medidata Release 9.0, 2020; Unger et al. 2021
SH-05National research prioritisation during an emergency Grade A
Effect
Headwind for non-priority studies: UK commercial recruitment −44% from 2017/18 to 2021/22; UK rank for trials initiated fell from 4th to 10th.
What helped
Explicit triage protected the platform trials (RECOVERY and Solidarity).
What did not
A reputational spiral of reduced allocations that had not reversed by 2022/23.
Sources
O'Shaughnessy review 2023; CSO Scotland 2020
SH-06Regional war in a study country Grade A
Effect
Recruiting sites −48% at 7 months and −62% at 13 months with no recovery; new-study starts about a third of pre-war three years on; the rate at surviving sites is unknown (grade A for sites, C for rate).
What helped
Transfers within country (115) and abroad (196) in four months; land IMP routes; direct-to-patient IMP; home blood draws; emergency ethics-committee meetings; 386 amendments.
What did not
A one-to-two-month national IMP buffer; narrow visit windows; consent language mismatch; a three-year sponsor absence.
Sources
Phesi via Lab News 2022 and 2023; Clinical Leader 2026; DIA Global Forum 2023

Source: epiClinical evidence review, October 2026; each entry's grade, sources and outcomes are the review's.